PYXS
Pyxis Oncology Inc
2.90$
-9.3%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | -14.2% | |
| – | – | +181.8% | +46.8% | +8.9% | -76.3% | +402.7% | |
| – | – | – | – | – | – | -26.8% | |
| – | +602.9% | +493.4% | +68.7% | -42.4% | +18.5% | +25.4% | |
| – | +132.4% | +385.3% | +100.1% | -12.7% | -22.0% | -12.7% | |
| – | +332.4% | +460.0% | +77.1% | -33.4% | +27.9% | -8.8% | |
| – | – | – | – | – | – | – | |
| – | – | – | -55.8% | – | – | – | |
| – | – | – | – | – | – | – | |
| – | – | – | -149.7% | – | -221.8% | – | |
| – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – |
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.